Ann Arbor, MI
Dr. Gregory P. Kalemkerian
Northwestern University Medical School, Chicago, IL - 1985
Northwestern Memorial Hospital, Chicago, IL - 1988
Johns Hopkins Hospital, Baltimore, MD - 1993
Dr. Gregory P. Kalemkerian is a medical oncologist and professor of medical oncology at the University of Michigan Health System. Prior to assuming his post at the University of Michigan in 1999, Dr. Kalemkerian served in the role of a physician-scientist at Wayne State University's Karmanos Cancer Institute's lung cancer program located in Detroit. During his time there, from the years 1993-1999, Dr. Kalemkerian's research centered upon the development of experimental therapies for lung cancer.
Dr. Kalemkerian earned his medical degree in 1985 and completed his residency in internal medicine in 1988 at Northwestern University located in Chicago, Illinois. Dr. Kalemkerian then went on to pursue a clinical and research fellowship (medical oncology) at the Johns Hopkins Hospital Oncology Center in Baltimore, Maryland which he completed in 1993.
Clinical and Laboratory Research
Board-certified in internal medicine and medical oncology, Dr. Kalemkerian's clinical focus is in the area of thoracic oncology—lung cancer, mesothelioma, and thymoma. His research interests are centered on clinical trials that evaluate new treatments for these diseases.
Since his arrival in 1999 at the University of Michigan, Dr. Kalemkerian has overseen the care of over 5,000 patients. He is considered by his colleagues as a leader in his field, possessing a superior level of knowledge regarding thoracic malignancies and treatment options and his colleagues agree that his bedside manner is on par with his medical expertise. Dr. Kalemkerian places a great emphasis on developing relationships with his patients and their families making sure they understand their disease and the options available to them to treat it. Dr. Kalemkerian stated, "One of the most enjoyable aspects of my job is the occasional clinical situations when I made a significant, personal difference in the care of a particular person by thinking 'outside-the-box.'" When faced with cancers pertaining to the lungs, such as mesothelioma, patients should seek a doctor such as Dr. Kalemkerian who is always thinking "outside-the-box" with regard to achieving optimal patient outcomes and improving patient survival rates.
Dr. Kalemkerian directs the Multidisciplinary Lung Cancer Clinic at the University of Michigan, has an active role in clinical and laboratory research work conducted at the university, and chairs the Small Cell Lung Cancer Guidelines Panel of the National Cancer Center Network. He is the author of over 50 research publications and has written numerous book chapters, editorials, and review articles.Sources
University of Michigan Health System